Dr. Reddy’s Laboratories has launched methylphenidate hydrochloride extended-release tablets USP 18 mg, 27 mg, 36 mg, and 54 mg. The generic product is a therapeutic equivalent of Janssen’s Concerta® extended-release tablets, 18 mg, 27 mg, 36 mg, and 54 mg, according to Dr. Reddy's.1

Methylphenidate hydrochloride extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged 6 years and older, adolescents, and adults up to age 65 years.2

Adverse reactions of methylphenidate hydrochloride extended-release tablets include decreased appetite, headache, dry mouth, nausea, insomnia, anxiety, dizziness, weight decreased, irritability, and hyperhidrosis.2


REFERENCES
  1. Dr. Reddy’s Laboratories announces the launch of methylphenidate hydrochloride extended-release tablets USP in the US market [news release]. Hyderabad, India & Princeton, NJ; September 3, 2020: BusinessWire. https://www.businesswire.com/news/home/20200903005324/en. Accessed September 8, 2020.
  2. Vermes K. Mylan Launches Generic Concerta and Zovia in the US Market. Pharmacy Times. https://www.pharmacytimes.com/news/mylan-launches-generic-concerta-and-zovia-in-the-us-market Published December 29, 2016. Accessed September 8, 2020.